Optimising Individualised prescribing with therapeutic drug Monitoring for Antipsychotics (OptIMA)3: clinical pilot study of antipsychotic drug level monitoring for dose review

Phase 1

• Conditions: Psychotic disorders; Mental and Behavioural Disorders

• Registration Number: ISRCTN76638113
• Lead Sponsor: King's College London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-11-12
• Study Completion: 2015-05-31
• Last Update Posted: 19 October 2020

Recruitment & Eligibility

• Status: Stopped
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

1. People admitted to participating inpatient wards or those under the care of an outpatient clinical service
2. People for whom the treating clinician has identified a need for antipsychotic dose review within routine clinical care
3. Age 18-65 years
4. Current diagnosis from one of the diagnostic categories of ICD-10: F20-F29
5. Regularly prescribed oral olanzapine or risperidone as monotherapy for the treatment of psychotic symptoms
6. Legally detained participants will be included if they have capacity to consent to the study

Exclusion Criteria

1. Current diagnosis of drug induced psychosis (ICD-10 F10-19)
2. Use of clozapine in past 12 months

Study & Design

• Study Type: Observational
• Study Design: Not specified